Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database.

Competing Interests: Conflict of Interest: C. Khouri has nothing to disclose. Conflict of Interest: A. Hlavaty has nothing to disclose. Conflict of interest: M. Roustit reports grants to institution (Grenoble University Hospital) for clinical research on diabetic foot ulcers from United Therapeutics; patent for Grenoble University PCT/EP2014/065093, device using treprostinil (Remodulin) to treat cutaneous ulcers; outside the submitted work. Conflict of Interest: J-L. Cracowski has nothing to disclose. Conflict of interest: M-C. Chaumais has nothing to disclose. Conflict of interest: M. Humbert reports grants paid to institution, consulting fees for steering committee, speaker fees, and advisory board membership from Acceleron, Janssen and Merck; speaker fees from AOP; outside the submitted work. Conflict of interest: D. Montani reports grants paid to institution from Acceleron, Janssen and Merck; consulting fees for steering committee from Acceleron; speaker fees from Bayer, Janssen and Merck; outside the submitted work.